Inclisiran vs PCSK9 Antibodies Show Equal Heart Protection Per LDL Drop

PCSK9 inhibition has become a cornerstone of cardiovascular risk reduction, but the two main therapeutic classes work very differently. Monoclonal antibodies (evolocumab, alirocumab) block the circulating PCSK9 protein from degrading LDL receptors, while RNA interference therapies (inclisiran) silence hepatic PCSK9 gene expression, preventing protein production altogether. Both lower LDL-cholesterol and apoB substantially, but whether the RNA interference approach translates into comparable clinical outcomes has been uncertain because long-term cardiovascular endpoint trial data for inclisiran are still maturing.

To address this, the research team performed genome-wide genotyping and RNA sequencing on 504 human liver samples to identify a genetic variant — rs472495 — that explained 5.6% of the variance in liver PCSK9 gene expression. This variant was used as a genetic instrument to mimic lifelong RNA interference of PCSK9. The established PCSK9 R46L loss-of-function variant, which reduces circulating PCSK9 protein levels and its functional activity, was used to model antibody-based PCSK9 inhibition. Both instruments were then deployed in drug-target Mendelian randomization analyses using large-scale GWAS datasets for multiple cardiometabolic outcomes.

For coronary artery disease (CAD), the primary endpoint, both genetic instruments yielded strikingly similar results when scaled per standard deviation decrease in apoB. The liver PCSK9 expression variant rs472495 was associated with an OR of 0.40 (95% CI: 0.31–0.51, P = 3.7×10⁻¹³), while the R46L protein-function variant yielded an OR of 0.48 (95% CI: 0.43–0.55, P = 1.3×10⁻²⁸). The confidence intervals overlapped substantially, and formal comparison tests showed no statistically significant difference between the two approaches for CAD risk reduction.

Beyond CAD, the researchers examined a broad panel of outcomes. Both genetic inhibition strategies showed comparable associations with reduced risk of ischemic stroke, heart failure, and aortic stenosis. On metabolic outcomes, both were associated with modestly increased type 2 diabetes risk — a known effect of LDL receptor upregulation improving glucose uptake into muscle and fat — and improved glycemic traits and non-alcoholic fatty liver disease markers. Liver enzyme profiles also shifted similarly between the two variants, reinforcing that the safety and pleiotropic effects appear to track with apoB and LDL-C reduction rather than the mechanism of PCSK9 inhibition.

The clinical implication is significant: it suggests inclisiran and similar RNA interference approaches should eventually produce cardiovascular outcome benefits comparable to PCSK9 antibodies, provided LDL-C and apoB reductions are equivalent. This supports using the two classes interchangeably based on patient preference, dosing convenience (inclisiran is given twice yearly vs. biweekly or monthly for antibodies), cost, and tolerability. The study does carry important caveats: Mendelian randomization approximates lifelong genetic exposure, not the shorter-term dynamics of pharmaceutical treatment, and the genetic instruments may not perfectly recapitulate the pharmacology of each drug class. Nonetheless, this genetic evidence provides strong prior support for ongoing outcomes trials of RNA interference-based lipid-lowering agents.